News

ImmuneRegen BioSciences (ImmuneRegen), a subsidiary of IR Biosciences Holdings, has provided an update on the understanding of the mechanisms underlying the immunostimulatory activity of its development candidate, Homspera.

Community Health Systems’ subsidiary has entered into an affiliation agreement with Rockwood Clinic, with 32 locations across the Inland Northwest region of the State of Washington. The transaction

Rigel Pharmaceuticals (Rigel) has received a milestone payment from Daiichi Sankyo as part of their collaboration to research and develop cancer treatments aimed at selectively inhibiting ligases, which

Eli Lilly and Kowa Pharmaceuticals America (Kowa) have entered into a co-promotion agreement in the US to commercialise Livalo (pitavastatin). Lilly and Kowa have also entered into a

Ligand Pharmaceuticals has completed the acquisition of Neurogen following approval of the transaction by Neurogen stockholders. As a result, Ligand gains a fully funded partnership with Merck &

The Medicines Company has reported the exclusive worldwide licensing of ApoA-I Milano from Pfizer. The company claims that ApoA-I Milano is a naturally occurring variant of a protein

The FDA has approved Sanofi Pasteur’s Fluzone High-Dose, an inactivated influenza virus vaccine for people aged 65 years and older, to prevent disease caused by influenza virus subtypes

Pfizer Canada has reported that following a priority review, Health Canada has approved Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)) for children aged six weeks through

Novartis is expected to gain exclusive worldwide rights to relaxin, a recombinant version of a naturally occurring human peptide, through the acquisition of Corthera. Relaxin is currently in